Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $251.4 million.

  • CG Oncology's Change in Acquisitions & Divestments rose 2491.56% to $251.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $850.1 million, marking a year-over-year increase of 1375.75%. This contributed to the annual value of $745.4 million for FY2024, which is 8803.78% up from last year.
  • As of Q3 2025, CG Oncology's Change in Acquisitions & Divestments stood at $251.4 million, which was up 2491.56% from $170.4 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Change in Acquisitions & Divestments peaked at $251.4 million during Q3 2025, and registered a low of $30.7 million during Q3 2023.
  • Over the past 3 years, CG Oncology's median Change in Acquisitions & Divestments value was $200.1 million (recorded in 2025), while the average stood at $180.9 million.
  • Data for CG Oncology's Change in Acquisitions & Divestments shows a peak YoY increase of 55635.68% (in 2024) and a maximum YoY decrease of 80.98% (in 2024) over the last 5 years.
  • Over the past 3 years, CG Oncology's Change in Acquisitions & Divestments (Quarter) stood at $230.0 million in 2023, then decreased by 0.81% to $228.2 million in 2024, then grew by 10.17% to $251.4 million in 2025.
  • Its Change in Acquisitions & Divestments was $251.4 million in Q3 2025, compared to $170.4 million in Q2 2025 and $200.1 million in Q1 2025.